A
Ariosa Diagnostics
Ariosa Diagnostics is a molecular diagnostics company focused on improving patient care.
About Ariosa Diagnostics
Ariosa Diagnostics, operating through its website ariosadx.com, is a healthcare company specializing in prenatal screening. The company offers the Harmony prenatal test, a type of non-invasive prenatal test (NIPT). This test is designed to screen for chromosomal conditions such as trisomies, which are genetic disorders caused by an extra chromosome. The Harmony test can also determine the sex of the baby.
Ariosa Diagnostics primarily serves expectant parents and healthcare providers, including obstetricians and gynecologists. The company operates in the prenatal care market, which focuses on the health of pregnant women and their unborn babies.
The business model of Ariosa Diagnostics revolves around providing accurate and reliable prenatal screening tests. The Harmony test is performed as early as 10 weeks into pregnancy using a simple blood draw. This test analyzes cell-free DNA (cfDNA) from the fetus that is present in the mother's blood. Unlike traditional invasive tests, the Harmony test poses no risk of pregnancy loss, making it a safer option for prenatal screening.
Ariosa Diagnostics generates revenue by selling the Harmony test to healthcare providers and directly to consumers. The company also partners with clinics and hospitals to offer its test as part of their prenatal care services. By positioning itself as both a provider of high-quality tests and a healthcare partner, Ariosa Diagnostics aims to build long-term relationships with its clients.
In summary, Ariosa Diagnostics is a key player in the prenatal screening market, offering a non-invasive, reliable, and early-detection test for chromosomal conditions and fetal sex determination. The company serves expectant parents and healthcare providers, making money through test sales and partnerships with medical institutions.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Founded
- 2008
- Headquarters
- San Jose, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Analytics, Biotechnology, Molecular, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2012 | $53M | $211M | Meritech Capital · Venrock | — |
| SERIES BOther financing | May 2010 | $13M | $51M | Venrock | — |
Growth signals
Latest recorded traffic for Ariosa Diagnostics is 35K monthly website visits, down 53.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later1 investor entered at this stage
Other known investors2 additional known investors
BioCube
Domain Associates
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ariosa Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ariosa Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.